Ditto Biosciences

Ditto Biosciences develops innovative therapies aimed at autoimmune diseases by harnessing biological mechanisms of parasites, utilizing advanced AI technologies for drug discovery. Founded in 2025 and headquartered in San Francisco, US, Ditto Biosciences focuses on drug discovery. The company has engaged in a significant pivot towards AI-driven therapies for autoimmune diseases. The firm has successfully completed 1 deal to date, with the most recent deal dated March 16, 2026, securing funding from Pioneer Fund.

Ditto Bio specializes in drug discovery by leveraging biological mechanisms of parasites to target autoimmune diseases. Its core offering includes an AI platform that identifies and evaluates proteins from viruses, ticks, and worms, aiming to modulate the immune system for conditions such as rheumatoid arthritis, eczema, and multiple sclerosis. The primary users of these innovations are pharmaceutical companies and research institutions, with a focus on key global markets including North America, Europe, and parts of Asia. Ditto Bio's revenue model is built around partnerships with pharmaceutical companies and research organizations, focusing on B2B transactions.

The company engages in collaborative agreements that allow clients to access its AI-driven platform and discoveries, typically involving licensing agreements or joint ventures with upfront fees or royalties based on the commercialization of resulting therapeutics. The unique approach to drug discovery positions Ditto Bio as a strategic partner in the pharmaceutical industry. Looking ahead, Ditto Biosciences is focused on launching new products leveraging its AI platform in 2026. The company plans to expand into new markets in Europe and Asia by the end of 2026.

The recent Seed funding raised in March 2026 will be utilized to support these product launches and market expansion efforts.